Innovative drug discovery speeds new treatments to patients
Drawing on the wealth of available data about human biology and genomics, as well as the in-house expertise of a global network of researchers, NIBR has developed new and important therapies.
Oct 27, 2013
At its core is NIBR’s emphasis on scientific exploration and experimentation, reflecting a realization that the development of significant advances depends on a focus on the long term, rather than on immediate financial returns. Fishman infuses his organization with the drive, as well as the opportunity, to tackle difficult challenges in order to bring forward treatments that he hopes will change the practice of medicine.
Think of the opportunities. We can now interrogate the entire genome in a single experiment, rather than going gene by gene. We generate petabytes of data, which is an amount I can't really comprehend.
“It’s all about the patients and the science,” explains Fishman.
We had an opportunity to sit down with Fishman. The accompanying video provides a glimpse into the philosophy and vision that has helped make NIBR’s pipeline of new medicines one of the leading in the industry.
This article contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as “expects,” or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the U.S. Securities and Exchange Commission. Novartis is providing this information as of this date and does not undertake any obligation to update it in the future.